Cancer Stem Cell-targeted Antibody-drug Conjugates for Cancer Immunotherapy

Area of Science:

• Oncology
• Immunotherapy
• Drug Development

Background:

• Cancer stem cells (CSCs) are crucial in cancer initiation, metastasis, and treatment resistance.
• Antibody-drug conjugates (ADCs) are emerging as a targeted therapy to eradicate CSCs and prevent recurrence.

Purpose of the Study:

• To review the mechanisms, recent advancements, and future prospects of ADCs targeting CSCs.
• To highlight the potential of CSC-targeted ADCs in revolutionizing precision oncology and cancer immunotherapy.

Main Methods:

• ADCs utilize monoclonal antibodies against CSC surface markers (e.g., CD44, CD133) conjugated to cytotoxic payloads.
• Internalization upon antigen binding triggers payload release and CSC apoptosis.
• Preclinical studies evaluated CD133- and CD44-targeted ADCs in various cancers; EpCAM-targeted ADCs showed efficacy in epithelial tumors.

Main Results:

• CSC-targeted ADCs, including those against CD133, CD44, and EpCAM, demonstrate efficacy in preclinical cancer models.
• Recent ADC technology advancements improve selectivity and reduce toxicity.
• Emerging strategies like bispecific antibodies and optimized linkers enhance ADC potential.

Conclusions:

• CSC-targeted ADCs represent a significant advancement in precision oncology, offering a strategy to overcome cancer stemness and therapy resistance.
• Challenges include CSC heterogeneity and biomarker specificity, requiring further innovation in ADC engineering and combination therapies.
• Continued research and clinical evaluation are essential to realize the full potential of CSC-targeted ADCs in cancer treatment.